ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) - ENCORE

Insmed Incorporated0 个研究点目标入组 250 人开始时间: 2020年9月28日最近更新: 2024年6月18日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Insmed Incorporated
入组人数: 250

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects must satisfy all of the following criteria to be included in the study:
•1. Male or female = 18 years of age (20 years or older in Japan)
•2. Current diagnosis of MAC lung infection. MAC or mixed infection with MAC as the dominant species allowed, with MAC as the intended organism for treatment
•3. Positive sputum culture for MAC within 6 months prior to Screening
•4. Positive sputum culture for MAC at Screening
•5. A high-resolution chest computed tomography (CT) scan or chest CT scan with contrast, read locally, within 6 months prior to Screening. Subjects who do not have a chest CT scan within 6 months prior to Screening will be required to obtain a high-resolution chest CT scan or chest CT scan with contrast, read locally, during Screening.
•6. In the Investigator’s opinion, documented respiratory signs/symptoms at Screening that are attributable to the current MAC lung infection.
•7. An average QOL-B respiratory domain score of = 85 based on scores at Screening and on the day of enrollment prior to randomization.
•8. In the Investigator’s opinion, underlying lung disease (eg. COPD, bronchiectasis) have been managed according to best local standard of care, and on stable maintenance therapy for a minimum of 4 weeks prior to randomization.
•9. Adherence to a predefined multidrug antimycobacterial regimen during the study.
•10. Ability to produce (spontaneously or with induction) approximately 2 mL of sputum for mycobacteriology at Screening.
•11. Women of child bearing potential (WOCBP) agrees to practice an acceptable method of birth control (eg, true abstinence [refraining from heterosexual intercourse during the entire study], copper intrauterine device (IUD), hormonal methods (levonorgestrel-releasing intrauterine system, progestogen implant, combined oral contraceptive pill [combined with barrier method] or double barrier method plus a spermicidal agent, exclusive homosexual relationship, or sole male partner who has undergone surgical sterilization with confirmation of azoospermia at least 3 months post procedure), while participating in the study.
•12. Provide signed informed consent prior to administration of any study drug or performing any study related procedure.
•13. Ability to comply with study drug use, study visits, and study procedures as defined by the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 200
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 50

排除标准

•Subjects who meet any of the following criteria will be disqualified from entering the study:
•1. Diagnosis of cystic fibrosis (CF).
•2. History of more than 3 MAC lung infections.
•3. Received any mycobacterial antibiotic treatment for current MAC lung infection
•4. Refractory MAC lung infection, defined as having positive MAC cultures while being treated with a multidrug mycobacterial antibiotic treatment regimen for a minimum of 6 consecutive months and no documented successful treatment, defined as negative sputum culture for MAC and cessation of treatment.
•5. Relapse of prior MAC lung infection, defined as positive sputum culture for MAC =6 months of cessation of prior successful treatment
•6. MAC isolate with MIC for amikacin = 128 µg/mL at Screening.
•7. Evidence of any pulmonary cavity = 2 cm in diameter, as determined by chest CT scan, read locally, within 6 months prior to Screening.
•8. Radiographic finding of new lobar consolidation, atelectasis, significant pleural effusion, or pneumothorax during routine clinical care within 2 months prior to Screening.
•9. Active pulmonary malignancy (primary or metastatic) or any malignancy requiring chemotherapy or radiation therapy within 1 year prior to Screening or anticipated during the study.
•10. Active pulmonary tuberculosis requiring treatment during Screening.
•11. Hospitalization for underlying lung disease at Screening.
•12. Acute pulmonary exacerbation (eg, COPD or bronchiectasis) requiring treatment with antibiotics, or corticosteroids (intravenous [IV] or oral), within 4 weeks prior to and during Screening.
•13. Predicted forced expiratory volume in 1 second (FEV1) < 35%, pre-bronchodilator use.
•14. Current smoker.
•15. History of lung transplantation.
•16. Use of inhaled or systemic aminoglycosides with activity against MAC (eg, amikacin, kanamycin, or streptomycin) during Screening.
•17. Prior exposure to ALIS (including clinical study).
•18. Known hypersensitivity to aminoglycosides.
•19. Disseminated MAC infection.
•20. Positive pregnancy test or lactation at Screening. All WOCBP will be tested. Women not of child bearing potential are defined as postmenopausal (ie, amenorrheic for 12 months without an alternative medical cause), or naturally or surgically sterile through bilateral oophorectomy, hysterectomy, or bilateral salpingectomy. For women under the age of 45, confirmatory testing with follicle stimulating hormone should be considered.
•21. Administration of any investigational drug within 8 weeks prior to Screening.
•22. Acquired and primary immunodeficiency syndromes (eg, HIV-positive, regardless of CD4 counts).
•23. Significant (as determined by the Investigator) hearing loss, vestibular dysfunction, neuromuscular weakness or a diagnosis of myasthenia gravis, where the potential risk of aminoglycoside toxicity outweighs the potential benefit.
•24. Aspartate aminotransferase or alanine aminotransferase = 3 times the upper limit of normal (ULN) or total bilirubin = 2 times ULN at Screening.
•25. Absolute neutrophil count = 500/µL at Screening.
•26. Serum creatinine > 2 times ULN at Screening.
•27. Current alcohol, medication, or illicit drug abuse.
•28. Any condition that, in the opinion of the Investigator, interferes with ability to safely complete the study or adhere to study requirements.

研究者

发起方

Insmed Incorporated

相似试验

进行中（未招募）

1 期

A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused by MACAdult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)MedDRA version: 22.1Level: LLTClassification code 10061229Term: Lung infectionSystem Organ Class: 100000004862

EUCTR2020-003079-16-ITINSMED INCORPORATED250

进行中（未招募）

1 期

EUCTR2020-003079-16-ATInsmed Incorporated400

进行中（未招募）

1 期

EUCTR2020-003079-16-GRInsmed Incorporated250

招募中

1 期

A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused by MACAdult Subjects with Newly Diagnosed Nontuberculous Mycobacterial(NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)MedDRA version: 22.1Level: LLTClassification code: 10061229Term: Lung infection Class: 10021881

CTIS2023-505273-33-00Insmed Inc.783

进行中（未招募）

1 期

EUCTR2020-003079-16-DKInsmed Incorporated400